DAY 2 – November 12, 2009

SESSION II: Acute Promyelocytic Leukemia: The Current State – Moderator: Martin S. Tallman, MD

8:00–8:20

What is the Function of the PML Protein?

Hugues de Thé, MD

8:20–8:40

Update on Molecular Mechanisms of APL

Pier Giuseppe Pelicci, MD, PhD

8:40–9:00

miRNA Networks in Leukemia

Clara Nervi, MD

9:00–9:20

Update on Animal Models of APL

Scott C. Kogan, MD

9:20–9:40

Long-Term Results with ATRA/Anthracycline-Based Strategies

Martin S. Tallman, MD

9:40–10:00

Arsenic as Initial Therapy for APL

Vikram Mathews, MD

10:00–10:30

Discussion

10:30–10:50

Break

WORKSHOP: Selective Apotosis Activators – Douglas R. Green, PhD, Moderator

10:50–11:10

A Brief History of Apoptosis

Douglas R. Green, PhD

11:10–11:30

Modulation of Metabolism for Cancer Therapy

Navdeep S. Chandel, PhD

11:30–11:50

Activating Tumor Suppressors to Kill Tumors

Gerard I. Evan, PhD

11:50–12:10

TRAIL Induction in Differentiation Therapy

Hinrich J. Gronemeyer, PhD

12:10–12:30

TBD

Michael Andreeff, MD, PhD

12:30–1:00

Discussion

01:00–2:30

Lunch/Poster Walk

Session III: Myelodysplasia: Mechanisms and Targets – Leonidas C. Platanias, MD, PhD, Moderator

2:30–2:50

5q- and Lenalidomide

TBD

2:50–3:10

Targeting SHP2 in Myeloid Malignancy

Elizabeth Eklund, MD

3:10–3:30

p38 and mTOR as a Target in MDS

Leonidas C. Platanias, MD, PhD

3:30–3:50

CD44–Differentiation and the Stem Cell Niche

Christine Chomienne, MD, PhD

3:50–4:30

Discussion

*Faculty not yet confirmed

Day 1 AgendaDay 3 AgendaDay 4 AgendaBack to Top